However, it is known that the lifetime breast cancer risk for carriers of CHECK2 PGVs is only 25–30% equal to that of ATM PGV carriers, but lower than that related to PALB2 (40–60%) and TP53 (40%) PGV carriers. Here, TP53 is linked to breast cancer.